Published in Circ Res on January 07, 2010
Titin is a target of matrix metalloproteinase-2: implications in myocardial ischemia/reperfusion injury. Circulation (2010) 1.80
Transgenic overexpression of matrix metalloproteinase-9 in macrophages attenuates the inflammatory response and improves left ventricular function post-myocardial infarction. J Mol Cell Cardiol (2012) 1.69
Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. Fibrogenesis Tissue Repair (2012) 1.65
Retracted Cardioprotective activity of placental growth factor in a rat model of acute myocardial infarction: nanoparticle-based delivery versus direct myocardial injection. BMC Cardiovasc Disord (2014) 1.44
Loss of Apelin exacerbates myocardial infarction adverse remodeling and ischemia-reperfusion injury: therapeutic potential of synthetic Apelin analogues. J Am Heart Assoc (2013) 1.05
Disrupting the EMMPRIN (CD147)-cyclophilin A interaction reduces infarct size and preserves systolic function after myocardial ischemia and reperfusion. Arterioscler Thromb Vasc Biol (2011) 1.02
Tissue inhibitor of metalloproteinases (TIMPs) in heart failure. Heart Fail Rev (2012) 1.01
Myofibroblasts and the extracellular matrix network in post-myocardial infarction cardiac remodeling. Pflugers Arch (2014) 0.98
Early activation of matrix metalloproteinases underlies the exacerbated systolic and diastolic dysfunction in mice lacking TIMP3 following myocardial infarction. Am J Physiol Heart Circ Physiol (2010) 0.98
Targeting matrix metalloproteinases in heart disease: lessons from endogenous inhibitors. Biochem Pharmacol (2014) 0.95
Molecular imaging of macrophage protease activity in cardiovascular inflammation in vivo. Thromb Haemost (2011) 0.95
Matrix metalloproteinases (MMP-2,9) and their tissue inhibitors (TIMP-1,2) as novel markers of stress response and atherogenesis in children with chronic kidney disease (CKD) on conservative treatment. Cell Stress Chaperones (2010) 0.93
Aging and the cardiac collagen matrix: Novel mediators of fibrotic remodelling. J Mol Cell Cardiol (2015) 0.91
Sexually dimorphic diet-induced insulin resistance in obese tissue inhibitor of metalloproteinase-2 (TIMP-2)-deficient mice. Endocrinology (2011) 0.90
MT1-MMP-dependent remodeling of cardiac extracellular matrix structure and function following myocardial infarction. Am J Pathol (2012) 0.89
Loss of Timp3 gene leads to abdominal aortic aneurysm formation in response to angiotensin II. J Biol Chem (2012) 0.89
Direct regulation of membrane type 1 matrix metalloproteinase following myocardial infarction causes changes in survival, cardiac function, and remodeling. Am J Physiol Heart Circ Physiol (2011) 0.88
Diabetes influences cardiac extracellular matrix remodelling after myocardial infarction and subsequent development of cardiac dysfunction. J Cell Mol Med (2012) 0.87
Autophagy mechanism of right ventricular remodeling in murine model of pulmonary artery constriction. Am J Physiol Heart Circ Physiol (2011) 0.87
Cardiomyopathy in the dystrophin/utrophin-deficient mouse model of severe muscular dystrophy is characterized by dysregulation of matrix metalloproteinases. Neuromuscul Disord (2012) 0.87
Characterization of epicardial-derived cardiac interstitial cells: differentiation and mobilization of heart fibroblast progenitors. PLoS One (2013) 0.84
Translating Koch's postulates to identify matrix metalloproteinase roles in postmyocardial infarction remodeling: cardiac metalloproteinase actions (CarMA) postulates. Circ Res (2014) 0.84
Using proteomics to uncover extracellular matrix interactions during cardiac remodeling. Proteomics Clin Appl (2013) 0.83
Membrane type 1-matrix metalloproteinase/Akt signaling axis modulates TNF-α-induced procoagulant activity and apoptosis in endothelial cells. PLoS One (2014) 0.82
Tissue inhibitor of metalloproteinase-2 gene delivery ameliorates postinfarction cardiac remodeling. Clin Transl Sci (2011) 0.82
Folic acid mitigated cardiac dysfunction by normalizing the levels of tissue inhibitor of metalloproteinase and homocysteine-metabolizing enzymes postmyocardial infarction in mice. Am J Physiol Heart Circ Physiol (2010) 0.82
The complex regulation of tanshinone IIA in rats with hypertension-induced left ventricular hypertrophy. PLoS One (2014) 0.82
TIMP-2 mutant decreases MMP-2 activity and augments pressure overload induced LV dysfunction and heart failure. Arch Physiol Biochem (2013) 0.80
Hemodialysis removes uremic toxins that alter the biological actions of endothelial cells. PLoS One (2012) 0.80
Adipose extracellular matrix remodelling in obesity and insulin resistance. Biochem Pharmacol (2016) 0.78
Differential effects of tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 on atherosclerosis and monocyte/macrophage invasion. Cardiovasc Res (2015) 0.78
Tissue Inhibitor of Metalloproteinase-2 Suppresses Collagen Synthesis in Cultured Keloid Fibroblasts. Plast Reconstr Surg Glob Open (2015) 0.75
Mitral tissue inhibitor of metalloproteinase 2 is associated with mitral valve surgery outcome. PLoS One (2014) 0.75
Inhibition of Soluble Epoxide Hydrolase Limits Mitochondrial Damage and Preserves Function Following Ischemic Injury. Front Pharmacol (2016) 0.75
Impact of percutaneous coronary intervention on biomarker levels in patients in the subacute phase following myocardial infarction: the Occluded Artery Trial (OAT) biomarker ancillary study. BMC Cardiovasc Disord (2013) 0.75
Using the laws of thermodynamics to understand how matrix metalloproteinases coordinate the myocardial response to injury. Metalloproteinases Med (2015) 0.75
Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature (2002) 5.02
Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell (2002) 4.35
Transcriptome-wide identification of novel imprinted genes in neonatal mouse brain. PLoS One (2008) 4.03
Regional loss of imprinting and growth deficiency in mice with a targeted deletion of KvDMR1. Nat Genet (2002) 3.88
Abnormal TNF activity in Timp3-/- mice leads to chronic hepatic inflammation and failure of liver regeneration. Nat Genet (2004) 2.96
Contribution of intimal smooth muscle cells to cholesterol accumulation and macrophage-like cells in human atherosclerosis. Circulation (2014) 2.67
Circadian rhythm disorganization produces profound cardiovascular and renal disease in hamsters. Am J Physiol Regul Integr Comp Physiol (2008) 2.62
Avian influenza risk perception, Europe and Asia. Emerg Infect Dis (2007) 2.43
Regulation of cardiac excitation-contraction coupling by action potential repolarization: role of the transient outward potassium current (I(to)). J Physiol (2003) 2.19
Role for piRNAs and noncoding RNA in de novo DNA methylation of the imprinted mouse Rasgrf1 locus. Science (2011) 2.17
Antagonism between DNA and H3K27 methylation at the imprinted Rasgrf1 locus. PLoS Genet (2008) 2.08
Regulation of DNA methylation of Rasgrf1. Nat Genet (2001) 2.06
Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nat Med (2003) 2.04
Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation (2007) 2.03
Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney Int (2008) 1.99
Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice. Hepatology (2009) 1.83
Titin is a target of matrix metalloproteinase-2: implications in myocardial ischemia/reperfusion injury. Circulation (2010) 1.80
Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes (2009) 1.78
Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation (2010) 1.77
Insulin-like growth factor-1 and PTEN deletion enhance cardiac L-type Ca2+ currents via increased PI3Kalpha/PKB signaling. Circ Res (2006) 1.71
Real-time analysis and selection of methylated DNA by fluorescence-activated single molecule sorting in a nanofluidic channel. Proc Natl Acad Sci U S A (2012) 1.70
Initial binding and recellularization of decellularized mouse lung scaffolds with bone marrow-derived mesenchymal stromal cells. Tissue Eng Part A (2011) 1.65
Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. Fibrogenesis Tissue Repair (2012) 1.65
Angiotensin 1-7 mediates renoprotection against diabetic nephropathy by reducing oxidative stress, inflammation, and lipotoxicity. Am J Physiol Renal Physiol (2014) 1.64
Cardiac-specific overexpression of sarcolipin inhibits sarco(endo)plasmic reticulum Ca2+ ATPase (SERCA2a) activity and impairs cardiac function in mice. Proc Natl Acad Sci U S A (2004) 1.63
Role of phosphoinositide 3-kinase {alpha}, protein kinase C, and L-type Ca2+ channels in mediating the complex actions of angiotensin II on mouse cardiac contractility. Hypertension (2010) 1.59
Muscle-specific loss of apoptosis-inducing factor leads to mitochondrial dysfunction, skeletal muscle atrophy, and dilated cardiomyopathy. Mol Cell Biol (2005) 1.58
Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury. Am J Pathol (2007) 1.55
Angiotensin-converting enzyme 2 attenuates oxidative stress and VSMC proliferation via the JAK2/STAT3/SOCS3 and profilin-1/MAPK signaling pathways. Regul Pept (2013) 1.54
Loss of p47phox subunit enhances susceptibility to biomechanical stress and heart failure because of dysregulation of cortactin and actin filaments. Circ Res (2013) 1.54
Comparative assessment of detergent-based protocols for mouse lung de-cellularization and re-cellularization. Tissue Eng Part C Methods (2012) 1.54
Single molecule epigenetic analysis in a nanofluidic channel. Anal Chem (2010) 1.52
A novel mutation in the RYR2 gene leading to catecholaminergic polymorphic ventricular tachycardia and paroxysmal atrial fibrillation: dose-dependent arrhythmia-event suppression by β-blocker therapy. Can J Cardiol (2011) 1.50
Heterozygote loss of ACE2 is sufficient to increase the susceptibility to heart disease. J Mol Med (Berl) (2014) 1.45
Tissue inhibitor of metalloproteinase 3 regulates TNF-dependent systemic inflammation. J Immunol (2006) 1.45
Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2. Hypertension (2010) 1.45
Inducible reprogramming of human T cells into Treg cells by a conditionally active form of FOXP3. Eur J Immunol (2008) 1.45
Rasgrf1 imprinting is regulated by a CTCF-dependent methylation-sensitive enhancer blocker. Mol Cell Biol (2005) 1.43
Gender-dependent aortic remodelling in patients with bicuspid aortic valve-associated thoracic aortic aneurysm. J Mol Med (Berl) (2014) 1.43
Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy. PLoS Pathog (2012) 1.42
Metzincin proteases and their inhibitors: foes or friends in nervous system physiology? J Neurosci (2010) 1.41
Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc Res (2007) 1.40
TIMP-3 deficiency leads to dilated cardiomyopathy. Circulation (2004) 1.36
Type 1 diabetic cardiomyopathy in the Akita (Ins2WT/C96Y) mouse model is characterized by lipotoxicity and diastolic dysfunction with preserved systolic function. Am J Physiol Heart Circ Physiol (2009) 1.36
Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. Am J Pathol (2006) 1.35
Individual Timp deficiencies differentially impact pro-MMP-2 activation. J Biol Chem (2006) 1.34
DNA methylation, imprinting and cancer. Eur J Hum Genet (2002) 1.32
Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am J Physiol Heart Circ Physiol (2008) 1.32
Comparative proteomics profiling of a phospholamban mutant mouse model of dilated cardiomyopathy reveals progressive intracellular stress responses. Mol Cell Proteomics (2007) 1.31
Metalloproteinase inhibitor TIMP-1 affects hepatocyte cell cycle via HGF activation in murine liver regeneration. Hepatology (2005) 1.31
Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circ Heart Fail (2009) 1.29
Tissue inhibitor of metalloproteinase-2 promotes neuronal differentiation by acting as an anti-mitogenic signal. J Neurosci (2005) 1.25
A rapid lung de-cellularization protocol supports embryonic stem cell differentiation in vitro and following implantation. Tissue Eng Part C Methods (2012) 1.25
Coordinate regulation of DNA methylation and H3K27me3 in mouse embryonic stem cells. PLoS One (2013) 1.24
Cardiac-specific overexpression of sarcolipin in phospholamban null mice impairs myocyte function that is restored by phosphorylation. Proc Natl Acad Sci U S A (2006) 1.24
A survey for novel imprinted genes in the mouse placenta by mRNA-seq. Genetics (2011) 1.24
Tissue inhibitor of metalloproteinase-2 (TIMP-2) regulates myogenesis and beta1 integrin expression in vitro. Exp Cell Res (2007) 1.23
Single-molecule analysis of combinatorial epigenomic states in normal and tumor cells. Proc Natl Acad Sci U S A (2013) 1.21
Sources of information and health beliefs related to SARS and avian influenza among Chinese communities in the United Kingdom and The Netherlands, compared to the general population in these countries. Int J Behav Med (2009) 1.20
Tumor necrosis factor-alpha-converting enzyme is a key regulator of agonist-induced cardiac hypertrophy and fibrosis. Hypertension (2009) 1.19
Increased medial degradation with pseudo-aneurysm formation in apolipoprotein E-knockout mice deficient in tissue inhibitor of metalloproteinases-1. Circulation (2003) 1.18
FRED (a Framework for Reconstructing Epidemic Dynamics): an open-source software system for modeling infectious diseases and control strategies using census-based populations. BMC Public Health (2013) 1.18
Tissue inhibitor of metalloproteinase-1 deficiency amplifies acute lung injury in bleomycin-exposed mice. Am J Respir Cell Mol Biol (2005) 1.17
miR-33a modulates ABCA1 expression, cholesterol accumulation, and insulin secretion in pancreatic islets. Diabetes (2012) 1.16
Trans allele methylation and paramutation-like effects in mice. Nat Genet (2003) 1.15
T₁ mapping with cardiovascular MRI is highly sensitive for Fabry disease independent of hypertrophy and sex. Circ Cardiovasc Imaging (2013) 1.15
Persistent macrophage/microglial activation and myelin disruption after experimental autoimmune encephalomyelitis in tissue inhibitor of metalloproteinase-1-deficient mice. Am J Pathol (2006) 1.14
Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment. J Card Fail (2010) 1.14
Matrix metalloproteinase-7 and ADAM-12 (a disintegrin and metalloproteinase-12) define a signaling axis in agonist-induced hypertension and cardiac hypertrophy. Circulation (2009) 1.13
Myocardial ATGL overexpression decreases the reliance on fatty acid oxidation and protects against pressure overload-induced cardiac dysfunction. Mol Cell Biol (2011) 1.13
Differential inhibition of membrane type 3 (MT3)-matrix metalloproteinase (MMP) and MT1-MMP by tissue inhibitor of metalloproteinase (TIMP)-2 and TIMP-3 rgulates pro-MMP-2 activation. J Biol Chem (2003) 1.13
Lack of tissue inhibitor of metalloproteinases 2 leads to exacerbated left ventricular dysfunction and adverse extracellular matrix remodeling in response to biomechanical stress. Circulation (2011) 1.12
Loss of PTEN attenuates the development of pathological hypertrophy and heart failure in response to biomechanical stress. Cardiovasc Res (2008) 1.11
Tissue inhibitor of metalloproteinases-1 (TIMP-1) modulates neuronal death, axonal plasticity, and learning and memory. Eur J Neurosci (2005) 1.10